View all the latest information in acute myeloid leukemia, arranged by trials and clinical studies. Listed below are recently added trial updates.
FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML
On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication...
AAML1421 phase I/II trial of CPX-351 followed by FLAG in children with R/R AML
The treatment and long-term survival of childhood acute myeloid leukemia (AML) is often complicated by the cardiotoxicity...
Predicting response and eliminating resistance to venetoclax
Acute myeloid leukemia (AML) is a heterogeneous disease, both clinically and genetically. Upregulation of members of the anti-apoptotic...
Beat AML Master trial: can we use precision medicine to treat older patients with AML?
The Beat AML Master trial is an umbrella study which contains 11 sub-studies covering the most prominent subtypes...
Can HMA maintenance therapy improve eligibility for HSCT?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can...
CC-486 maintenance prolongs survival in older patients with AML in first remission
Despite reasonable initial responses with standard induction chemotherapy in elderly patients with acute myeloid...
Post-HSCT outcomes following treatment with gemtuzumab ozogamicin
Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to calicheamicin, is approved for newly diagnosed and...
The benefit of gemtuzumab ozogamicin in patients with AML depends on mutational status and level of CD33 expression
A study evaluating whether molecular events could predict the benefit of adding...